Menu Search
Equities

Oruka Therapeutics Inc

HQ1:STU

Oruka Therapeutics Inc

Actions
  • Price (EUR)24.20
  • Today's Change-0.20 / -0.82%
  • Shares traded0.00
  • 1 Year change+25.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.20m
  • Incorporated2004
  • Employees4.00
  • Location
    Oruka Therapeutics Inc10170 Church Ranch Way, Suite 100WESTMINSTER 80021United StatesUSA
  • Phone+1 (720) 940-2200
  • Fax+1 (302) 655-5049
  • Websitehttps://orukatx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ORKA:NMQ since
announced		Transaction
value
Oruka Therapeutics IncDeal completed03 Apr 202403 Apr 2024Deal completed25.00%--
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.